The AML Hub uses cookies on this website. They help us give you the best online experience. By continuing to use our website without changing your cookie settings, you agree to our use of cookies in accordance with our updated Cookie Policy

Could aspacytarabine be a new frontline therapy option for patients with AML that are unfit for IC?

Dec 17, 2019

During the 61st American Society of Hematology (ASH) meeting in Orlando, US, the AML Global Portal was delighted to speak to Selina Luger, University of Pennsylvania, Philadelphia, US. We asked: Could aspacytarabine be a new option for first-line therapy in patients with acute myeloid leukemia that are unfit for intensive chemotherapy?

Selina Luger explains that aspacytarabine, a cytarabine derivative, is effective and less toxic than cytarabine. Based on recent data, aspacytarabine is safe and efficacious for the treatment of AML patients who are unfit for standard chemotherapy.

Could aspacytarabine be a new frontline therapy option for patients with AML that are unfit for IC?